A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging
Launched by TRUDIAGNOSTIC · Mar 16, 2022
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
While current research has identified many mechanisms of action, effects and cell signaling benefits resulting from HBOT, we do not have a firm understanding of the timeframe and dosage for many of these expected adaptations. Data from this study will be collected and shared on an ongoing basis throughout the course of care. This research project will help us to confirm these cell-signaling changes and benefits, and also develop a better understanding of the necessary PO2 and time frame required in order to achieve these changes leading to improved patient outcomes in the field of hyperbari...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Any sex, gender orientation, and ethnicity
- • 2. Between ages 40 and 70
- • 3. Must be willing and able to participate in venipuncture, health history and clinical assessments, lab test assessment, hyperbaric oxygen treatment.
- • 4. Participants must also agree to maintain their current lifestyle choices consistent with pre- participation with this study. Participants should not change their exercise programs, diets, sleep patterns supplements or other. Any significant changes in their lifestyle choices must be reported to the staff.
- Exclusion Criteria:
- • 1. Significant change in diagnosis and/or treatment of major illness or injury within 2 years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric condition
- • 2. Any ongoing immune system concerns or immunodeficiency disease
- • 3. Body mass index (BMI) changes of more than 5% over the course of the study
- • 4. Changes in weight of more than 15 lbs. during the course of the study
- • 5. Presence of a severe active infection as determined by the principal investigator.
- • 6. Any other illness, disorder, alcohol or chemical dependence that in the opinion of investigators would render study participation unsuitable
- • 7. Unable or unwilling to provide required biological sample
- • 8. Unable or unwilling to avoid pregnancy during study period
- • 9. Presence of cataracts before the study begins
- • 10. Myopic changes within the first 30 days of treatment
About Trudiagnostic
TruDiagnostic is an innovative clinical trial sponsor specializing in advanced diagnostics and personalized medicine. By leveraging cutting-edge genomic technologies, TruDiagnostic aims to enhance the understanding of disease progression and treatment response through precision health solutions. The organization is committed to conducting rigorous clinical trials that generate actionable insights, ultimately improving patient outcomes and advancing the field of healthcare. With a focus on integrity, collaboration, and scientific excellence, TruDiagnostic is positioned at the forefront of transforming clinical research into practical applications for better healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Florham Park, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials